**Cost-effectiveness of romosozumab for severe postmenopausal osteoporosis at** 

**very high risk of fracture in Mexico.**

**Short title: Romosozumab vs teriparatide for postmenopausal osteoporosis at** 

**very high risk of fracture**

5 Juan Pablo Diaz Martinez<sup>1\*</sup>, Therese Aubry de Maraumont<sup>2</sup>, Elly Natty Sánchez<sup>2</sup>,

6 Luis Miguel Camacho Cordero<sup>2</sup>, Eric Yeh<sup>3</sup>

 *Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto,* 

*Canada;<sup>2</sup>Health Economics Amgen Mexico, Mexico City, Mexico, <sup>3</sup>Health Economics Amgen* 

9 \*Corresponding author: [juan.diaz.martinez@mail.utoronto.ca](mailto:juan.diaz.martinez@mail.utoronto.ca) (JPDM)

 **Introduction:** This study aims to assess the cost effectiveness of romosozumab versus teriparatide, both sequenced to denosumab, for the treatment of severe postmenopausal osteoporosis at very high risk of fractures in Mexican women. **Methods:** A Markov model was used to assess the relative cost effectiveness of 1 year of romosozumab versus 2 years of teriparatide, both sequenced to denosumab for a total treatment duration of 5 years. 15 Outcomes for a cohort of women with a mean age of 74 years, a T-score  $\leq$  -2.5 and a previous fragility fracture were simulated over a lifetime horizon. The analysis was conducted from the perspective of the Mexican healthcare system and used a discount rate of 5% per annum. To inform relative fracture incidence, the bone mineral density (BMD) advantage of romosozumab over teriparatide was translated into relative risks of fracture, using relationships provided by a meta-regression of osteoporosis therapy trials. Outcomes were assessed in terms of lifetime costs (2023 Mexican pesos), quality-adjusted life years (QALYs) and life-years gained (LYs). **Results:** Base case results showed that, compared with teriparatide/ denosumab, romosozumab/ denosumab reduced costs by \$51,363 MXN per patient and yielded 0.03 additional QALYs and 0.01 LYs. Scenario analyses and probabilistic sensitivity analyses confirmed that results are robust to uncertainty in model assumptions and inputs. **Conclusions:** Results show that romosozumab/ denosumab produces greater health benefits at a lower total cost than teriparatide/ denosumab.

## 28 **Introduction**

29 Osteoporosis is a chronic condition characterized by reduced bone strength, leading to an 30 increased susceptibility to fractures. The risk of fractures due to osteoporosis becomes more 31 prominent with advancing age, particularly among postmenopausal women (1). These fractures 32 have a significant economic impact globally, resulting in substantial direct and indirect costs (2). 33 In Mexico, the direct cost of more than 75,000 fragility fractures in 2010 amounted to \$256.2 34 million US dollars, and it was projected to grow by 41.7% by 2020 (3). The likelihood of 35 experiencing a hip fracture over a lifetime was estimated to be 8.5%. Fragility fractures, which 36 occur due to weakened bone strength from minimal trauma, can result in loss of independence 37 for patients and increased burden for both patients and their caregivers (4). They are also 38 associated with higher risks of disability, hospitalization, and mortality, which can persist for 39 several years, especially in the case of hip fractures (5,6). 40 Approximately one-third of postmenopausal women will experience a fragility fracture 41 associated with osteoporosis during their lifetime (7). Once a postmenopausal woman 42 experiences her first fracture due to osteoporosis, her risk for subsequent fractures increases 43 significantly, with a more than fivefold higher likelihood of suffering another fracture within one 44 year (8–10). A recent study showed that nearly 18% of individuals experienced a second 45 fragility fracture, and the median time to the occurrence of the second fracture was less than two

46 years (11).

47 Severe or established osteoporosis is diagnosed when a previous fracture is present and bone 48 mineral density (BMD), measured by dual-energy X-ray absorptiometry (DXA), is -2.5 standard 49 deviations or more below the mean value of a health young adult (12). According to a recent

50 consensus statement in Mexico, teriparatide and denosumab were recommended as treatment 51 options for severe osteoporosis (13). Furthermore, until 2022 teriparatide was the only therapy 52 approved for reimbursement in patients with severe postmenopausal osteoporosis at very high 53 risk of fracture (14). Teriparatide, an anabolic hormone, is recommended for individuals with 54 osteoporosis who have a history of previous hip or spinal fractures, are at a high risk of 55 refracture, and have not responded to bisphosphonate treatments. However, it should be noted 56 that teriparatide has not been proven to prevent hip fractures. Furthermore, in accordance with 57 the Clinical Practice Guidelines in Mexico for the management of osteoporosis in 58 postmenopausal women established by CENETEC (National Center for Excellence in Health 59 Technology), hip fractures remain prevalent and do not exhibit a decline. These fractures are 60 associated with significant morbidity, mortality, and financial burdens (15,16). 61 Romosozumab is a humanized monoclonal antibody which works by inhibiting the protein 62 sclerostin. It has a dual effect on the bones: it increases bone formation and decreases bone 63 resorption, unlike other bone-forming agents such as teriparatide, where both bone formation and 64 resorption are increased. Compared to bone-forming agents or aniresoptives, romosozumab 65 treatment duration is only one year. Romosozumab has undergone comprehensive investigation 66 to evaluate its potential in reducing the risk of fractures, with a focus on two Phase III studies 67 that incorporated primary and secondary fracture endpoints: the ARCH (17) and FRAME (18) 68 studies. Additionally, a separate study assessed the percentage change in a real bone mineral 69 density (BMD) at the total hip as an outcome measure (19) (STRUCTURE trial). Romosozumab 70 has been shown to increase trabecular and cortical bone mass, improve bone structure and 71 strength, and reduce the incidence of new vertebral fractures by 73% compared to placebo in just 72 one year of treatment. In comparison to teriparatide, romosozumab has demonstrated to double

73 the BMD at key sites: +4.4% in the spine, +2.4% in the hip, and +3% in the femur.



# 89 **Methods**

## 90 *Patient population*

91 The patient population modelled in this analysis consisted of a cohort of postmenopausal 92 osteoporotic women who were at very high risk for future fracture. In line with the ARCH trial, 93 the model included patients with a mean age of 74 years with a femoral neck BMD T-score  $\leq$ 

94 ― 2.5 and a history of fragility fracture. Based on previous clinical evidence, it was assumed 95 that 50% of patients had a single previous fracture, and 50% had multiple prior fractures (27).

### 96 *Time horizon, perspective, and discount rate*

97 Given that osteoporosis is a chronic disease, we used a lifetime time horizon to capture relevant 98 benefits and costs associated with treatment. An annual discount rate of 5% was applied to both 99 costs and future outcomes, in accordance with the Mexican HTA guidelines (14). Alternative 100 discount rates were considered in scenario analyses. The analysis was conducted from the

101 perspective of the public healthcare payer in Mexico.

## 102 *Comparators*

103 Our model compared two arms:



106 In the second arm, patients received teriparatide 20 μg daily for 24 months, sequenced to 107 denosumab, 60 mg every six months (teriparatide/denosumab)

108 The choice of these comparators relies on current guidelines for osteoporosis management in

109 Mexico (13). Romosozumab was administered for one year (consistent with the ARCH and

110 FRAME trials and the product label). Teriparatide was administered for 2 years consistent with

111 the clinical guidelines. Patients in both arms were assumed to be treated for a total of 5 years; a

112 commonly recommended duration for pharmacological osteoporosis therapy (28).

## 113 *Model structure*

114 A Markov state transition model with a 6-month cycle length was used to assess costs, life years 115 (LYs), and quality-adjusted life-years (QALYs) associated with the intervention arms. The 116 structure of the model was based on the model created by the International Osteoporosis 117 foundation. Such a model has been used widely as a basis to provide economic analyses of 118 osteoporosis (29–33). Markov models are especially appropriate to use when: 1) a problem 119 involves a continuous risk over time 2) the timing of events is important 3) events happen more 120 than once, which is the case for our decision-problem (34). 121 Seven Markov health states were considered (Fig1): baseline (at risk of fracture), clinical 122 vertebral fracture, post clinical vertebral fracture, hip fracture, post hip fracture, "other" fragility 123 fracture, and death. All patients started at the baseline state, and throughout each cycle, they 124 were at risk of sustaining a fracture (hip, vertebral, and other fracture) or death. A year after the 125 event, patients with a hip or vertebral fracture transitioned into the post-hip fracture or post-126 vertebral fracture state. On the other hand, patients with another type of fracture returned to the 127 "baseline" state.

# 128 **Figure 1 Structure of the Markov cohort model. Arrows to the health state "dead"**

129 **excluded for simplification** Fx, fracture; Vert, vertebral. Death can occur from any other state. 130 For simplicity, specific transitions are not shown.

131 The structure of the model is hierarchical, and the transition of the patient between the fracture 132 states is based on the severity of the fracture type. Regarding the highest cost and lower utility, 133 the most severe fracture is hip fracture, followed by vertebral fracture. Therefore, once the 134 patient has sustained a vertebral fracture, the patient cannot go back to the baseline, or to the 135 "other" fracture state(s). Similarly, patients that have sustained a hip fracture, cannot go back to



# 143 *Model inputs*

144 *Fracture risk*

145 The risk of sustaining a fracture in the model depends on three elements:

- 146 (1) The risk for an individual in the general population of incurring a fracture,
- 147 (2) The increased fracture risk associated with osteoporosis (the relative risk RR), and
- 148 (3) A risk reduction, if any, attributed to an intervention.

149 The general population risk depends on age and sex. The risk of fracture relative to the general 150 population depends on age, bone mineral density and previous fracture. Age-specific general 151 population rates of hip and vertebral fracture were derived from Ettinger et al (35). The 152 incidences of other osteoporotic fractures were derived from Melton et al (36). Other 153 osteoporotic fractures include ribs, pelvis, shaft/distal humerus, proximal humerus, clavicle, 154 scapula, sternum, distal forearm, tibia,1 and fibula fractures. For age-specific incidence, these 155 values were linearly interpolated or extrapolated as required to produce fracture rates for each 156 year of age. General population fracture rates used in the model are shown in Supplementary

# 157 Table 1.

158 To estimate fracture risks in untreated patients with severe postmenopausal osteoporosis, general 159 population fracture rates were adjusted for the lower BMD T-scores and higher prevalence of 160 previous fracture in the modelled population. Fracture risks for the patient population were 161 adjusted with RRs of subsequent fracture in patients with a prior vertebral fracture and RRs of 162 subsequent fracture per standard deviation decline in BMD, as described in previous economic 163 evaluations (24,32).

## 164 *Treatment efficacy*

165 For individuals undergoing treatment, the model incorporated data on the effectiveness of the 166 treatment, specifically in terms of the RRs of experiencing fractures. These RRs were applied 167 over time to the fracture rates observed in untreated very high-risk postmenopausal osteoporotic 168 patients. The efficacy data utilized in the model provided separate RRs for hip fractures, new 169 vertebral fractures, and nonvertebral fractures. The RRs associated with new vertebral fractures 170 were utilized to determine the treatment-specific efficacy in preventing vertebral fractures. 171 Similarly, the RRs of nonvertebral fractures informed the efficacy of the treatment in preventing 172 other types of fractures, including those affecting the wrist and all other non-hip, non-vertebral 173 fractures. The efficacy of preventing hip fractures was directly informed by the treatment-174 specific RRs of hip fracture.

175 For patients receiving romosozumab/denosumab, relative fracture incidence compared with no 176 treatment were derived by applying the RRs for romosozumab/denosumab versus denosumab 177 taken from a propensity-score matching (PSM) post-hoc analysis of the FRAME trial (37) to the 178 RRs for denosumab versus placebo from a network meta-analysis of osteoporosis therapies (38)

179 (Table 1). To allow for changing relative efficacy over time, parametric survival functions were 180 fitted to time-to-event data for hip and nonvertebral fractures (FRAME trial). Therefore, RRs 181 were calculated for each 6-month model cycle over the course of the 5-year treatment period. For 182 each arm of the FRAME trial (romosozumab/denosumab and denosumab), model fitting was 183 applied for each fracture type (hip and nonvertebral fractures). The parametric functional form 184 with the lowest Akaike information criterion (AIC) was selected, from exponential, Weibull, log-185 logistic, log-normal, Gompert, generalized gamma and gamma distributions. Selected regression 186 parameters are shown in Supplementary Table 2. This was not possible for vertebral fractures, 187 given that accurate time-to-event data were not available. Therefore, the RR of vertebral 188 fractures for romosozumab/denosumab versus denosumab were calculated from new vertebral 189 fracture incidence data from the FRAME trial, shown in Table 1. Efficacy estimates for 190 romosozumab/denosumab versus placebo from this exercise (i.e. applying RRs 191 romosozumab/denosumab versus denosumab to RRs for denosumab versus placebo) are shown 192 in Table 1.







194 NA. Not applicable; CI. confidence interval. \* Data for ≥month 36 is used given that is not available for this time period. + Derived from the parametric

195 functions.

196 For patients in the teriparatide/ denosumab arm, the efficacy in reducing fractures for this arm 197 compared to no treatment was determined by applying the RRs of fracture for teriparatide versus 198 romosozumab to the RRs for romosozumab/ denosumab versus placebo (described in the 199 previous paragraph).

200 To derive the RRs of fracture for teriparatide versus romosozumab, BMD efficacy results from 201 the STRUCTURE trial (19) were converted to fracture outcomes using the relationship between 202 percentage total hip BMD change from baseline and RRs of hip, vertebral, and nonvertebral 203 fracture on the log scale, provided by the meta-regression conducted by the FNIH Bone Quality 204 Study (39). While the regression equations were not directly reported in the publication, fracture 205 risk reductions associated with a 2%, 4%, and 6% improvement in BMD were available, which 206 were used to reproduce the parameters. The slopes of these equations were used to translate the 207 difference of 3.4% total hip BMD change from baseline for romosozumab versus teriparatide at 208 12 months in the STRUCTURE trial into RRs of fracture. BMD at the total hip was used in these 209 calculations due to its high predictive value for fractures (39). Resulting RRs of fracture for 210 romosozumab versus teriparatide are shown in Table 1. Full details of their derivation are shown 211 in Supplmentary Table 3. Given that the STRUCTURE trial exclusively offers relative BMD 212 efficacy data for romosozumab versus teriparatide at the 12-months, the model's base case 213 involves assuming that the fracture reduction advantage of romosozumab over teriparatide 214 endures until patients in both arms transition to denosumab, with the assumed duration being 2 215 years. Following this period, the model posits equal efficacy between romosozumab/ denosumab 216 and teriparatide/ denosumab. This assumption was explored in scenario analysis.

217

218 Finally, the STRUCTURE trial was conducted in subjects previously treated with

219 bisphosphonates. Given that newer osteoporosis therapies are often used as secondary prevention

- 220 treatments (41), this is likely to be consistent with the characteristics of patients receiving bone-
- 221 forming agents in clinical practice. However, to assess the cost effectiveness of romosozumab/
- 222 denosumab versus teriparatide/ denosumab in a treatment-naïve population, a scenario analysis
- 223 was conducted where BMD efficacy was taken from a romosozumab phase II trial (2.8%
- 224 difference in total hip change from baseline at 12 months), conducted in patients who were not
- 225 bisphosphonate pre-treated (40).

# 226 *Treatment persistence*

227 In practice, adherence to pharmacological osteoporosis treatments is often less than perfect (42). 228 Nevertheless, by recognizing that the controlled conditions of a randomized trial may not 229 accurately reflect treatment discontinuation in practical settings, the model's base case assumes 230 full persistence with all treatments. The model then explores the impact of imperfect persistence 231 through scenario analysis.

## 232 *Treatment offset time*

233 Although anti-fracture efficacy is likely to persist for a period of time (offset time) after a 234 treatment is stopped, there have been very few studies that report offset time and there is a lack 235 of consensus on the duration of offset time (29,43). As an example, some evidence has shown 236 that after 5 years' treatment with alendronate followed by 5 years' treatment with placebo, 237 patients' BMD remained at or above pre-treatment levels (43), indicating that the benefit of 238 pharmacological treatment persists for some time. Therefore, our model assumes that after the 5- 239 year treatment course, fracture reduction benefit declines linearly to 0 over the course of a further

## 240 5 years for both arms.

#### 241 *Mortality*

242 General population all-cause mortality was informed by life tables for females in Mexico from 243 the National Institute of Statistics and Geography (INEGI) (44). The model also accounted for 244 the increased risk of mortality following a fracture. Two key assumptions were made regarding 245 mortality following osteoporosis-related fractures: 1) 30% of the excess mortality following a 246 fracture was attributable to the fracture itself, in line with previous analyses (21,32) and 2) the 247 increased risk of mortality after hip and vertebral fractures was assumed to last for 8 years as per 248 previous analyses . This duration of excess mortality only applied to hip and vertebral fractures 249 as other fractures were assumed to only have effects in the first year of fracture. Due to lack of 250 Mexico-specific data related to mortality due to hip, clinical vertebral and other fractures, the 251 default values were derived using data from Sweden (20).

# 252 *Health-related quality of life*

253 The estimates of utility in the general population were obtained from the US (45). Utility 254 multipliers specific to the type of fracture were applied to this background age- and sex-specific 255 utility value. To account for the health-related quality of life (HRQoL) loss due to fracture, in the 256 first year after hip, vertebral, and other fracture, and for the second and subsequent years after 257 hip and vertebral fracture, utility multipliers were applied to utilities of the general population. 258 Data specific to subsequent "other" fractures were not available. Therefore, the utility multiplier 259 in the first year after "other" fracture was assumed to correspond to that of a distal forearm 260 fracture. These values were taken from Svedbom et al. (46). HRQoL inputs used in the model are 261 shown in Table 2.

# 262 **Table 2 Health-related quality of life, utilities, and drug, treatment**

# 263 **monitoring/administration, direct medical costs**





264 *Costs*

265 The model included drug acquisition costs, treatment monitoring/administration costs, and direct 266 medical costs due to fracture (Table 2). All costs were expressed in 2023 Mexican pesos (MXN), 267 inflated to 2023 values where required using the Consumer Price Index (CPI) for Mexico (51). 268 Drug acquisition costs were obtained from the manufacturer for romosozumab and from the list 269 prices from the Governmental Electronic System for Purchases (Compranet) (47). 270 For treatment monitoring/administration costs, the model assumed that patients receiving 271 treatment incurred the cost of a physician visit once a year, and the cost of a BMD measurement 272 every 2 years, as per on the IMSS inpatient and outpatient unit costs (48). The model assumed 273 that all patients treated with romosozumab required a monthly outpatient visit for subcutaneous 274 injection administration (outpatient consultation visit). This cost was obtained by the "Hospital 275 General Gea González" inpatient and outpatient unit costs (49) . Fracture morbidity costs 276 included the direct medical cost of fracture (50), applied for the year in which fracture occur. 277 *Analysis*

278 The model estimated total discounted lifetime costs, LYs (total and without fractures) and 279 QALYs for each intervention, with cost-effectiveness assessed in terms of incremental cost-280 effectiveness ratios (ICERs).

281 Our base case analysis considered LYs without fractures gained as the effectiveness of the

282 decision-making process. In Mexico, the willingness-to-pay threshold values are typically set at 283 1 to 3 times the Gross Domestic Product (GDP) per capita, which translates to approximately 284 \$200,000 to \$600,000 Mexican Pesos per LY gained. Our results were assessed through a 285 probabilistic model with 1,000 simulations, where parameters were varied simultaneously 286 according to distributions representing their uncertainty (52). Cost-effectiveness acceptability 287 curves (CEACs) were derived to summarize the proportion of probabilistic iterations in which 288 each comparator was cost-effective across a range of willingness to pay per QALY-gained 289 thresholds. In addition, sensitivity analyses using the deterministic model were performed to 290 assess the sensitivity of results to changes in individual parameters. Parameters were varied using 291 published confidence intervals or standard errors, where available, and by 20% above and below 292 point estimates where measures of uncertainty were unavailable. Cost-effectiveness was assessed 293 with the incremental net monetary benefit (INMB) for each deterministic sensitivity analysis.

294 Scenario analyses were conducted to assess the impact of using alternative model assumptions. 295 Scenario analyses around modelling assumptions were considered to account for annual discount 296 rates of 0 or 3%, treatment efficacy rates estimated from parametric models, modified treatment 297 offset time (1 year), increased excess mortality duration, using QALYs as instead of LYs, using a 298 different time horizon (5 years), and reduced duration of fracture reduction benefits associated 299 with romosozumab/ denosumab. We also considered relaxing the assumption of treatment 300 persistence, i.e., treatment discontinuation. Persistence data for denosumab were taken from an 301 analysis of osteoporotic patients in US Medicare Fee-for-Service data reported by Singer et al. 302 (53). Persistence with romosozumab and teriparatide were reported by Chien et al. (54).Cost-303 effectiveness was estimated across each intervention for each scenario.

# 304 **Results**

#### 305 *Base case results*

- 306 The total and disaggregated base case model results are presented in Table 3. Romosozumab/
- 307 denosumab yielded 7.85 LYs without fractures, and a total cost of \$213,925 MXN. Compared to
- 308 teriparatide/ denosumab, it was associated with a lifetime gain of .02 LYs, and a cost reduction
- 309 of \$46,61 MXN. Except for treatment monitory costs, all other costs (drug and morbidity costs)
- 310 were higher for those patients treated with teriparatide/ denosumab. Therefore, the improvements
- 311 in QALYs and cost reductions for romosozumab/ denosumab were driven by a reduction of the
- 312 expected number of fractures (2542.3 per 1000 patients versus 2572.2 for teriparatide/
- 313 denosumab). When considering QALYs, romosozumab/ denosumab mean estimate was 6.09 and
- 314 teriparatide/ denosumab 6.07. Consequently, teriparatide/ denosumab was dominated by
- 315 romosozumab/ denosumab independently of the measure of effectiveness.

#### 316 **Table 3 Base case lifetime cost-effectiveness results**



Vertebral fracture	\$27,758	\$29,071	$-$1,313$
Other fracture	\$47,388	\$47,777	$-$ \$389
<b>Total fracture costs</b>	\$132,663	\$135,204	$-$ \$2,542
Drug cost	\$74,606	\$119,884	$-$ \$45,278
<b>Treatment</b>	\$6,656	\$5,497	\$1,159
monitoring/administration cost			
<b>Total cost (discounted)</b>	\$213,925	\$260,586	$-$ \$46,661
<b>QALYs and life years</b>			
Life years without fractures	11.22	11.20	0.02
(undiscounted)			
Life years without fractures	7.85	7.83	0.02
(discounted)			
QALYs (undiscounted)	8.60	8.57	0.03
QALYs (discounted)	6.09	6.07	0.02
<b>Cost-effectiveness</b>			
<b>ICER</b>			Dominant

317 A dominant intervention produces superior health outcomes at a lower cost than teriparatide/ denosumab. ICER,

318 incremental cost-effectiveness ratio

- 319 In our probabilistic sensitivity analyses, 97% our simulations yield lower costs and more LYs
- 320 without fractures for romosozumab/ denosumab when compared to teriparatide/ denosumab
- 321 (Figure 2). The probability of romosozumab/ denosumab being cost-effective was 100%,
- 322 independently of the threshold chosen (Figure 3).

# 323 **Figure 2 Scatter plot of probabilistic results (incremental).** LY, life year

## 324 **Figure 3 Cost-effectiveness acceptability curves.** LY, life year

#### 325 *Deterministic sensitivity analyses and scenario analyses*

- 326 Deterministic sensitivity analysis results demonstrated that the model outcomes were the most
- 327 sensitive to the RR for vertebral fractures between denosumab vs placebo. None of the cost
- 328 variations proposed in this study had an impact on the model outcomes. Moreover,
- 329 romosozumab/ denosumab was consistently dominant, as it represented the highest INMB
- 330 relative to teriparatide/ denosumab for each run of the one-way sensitivity analysis (see Figure
- 331 4).

#### 332 **Figure 4 Tornado diagram of deterministic sensitivity analyses. Romosozumab/alendronate**

#### 333 **versus alendronate—discounted incremental net monetary benefit at a threshold of**

- 334 **\$600,000/QALY.** FRAME, FRActure study in postmenopausal woMen with ostEoporosis;
- 335 BMD, bone mineral density; Fx, fracture; QALY, quality-adjusted life year; RR, relative risk;
- 336 SD, standard deviation; vert, vertebral
- 337 The incremental costs, LYs, and ICER of romosozumab/ denosumab relative to teriparatide/
- 338 denosumab for all scenarios are presented in Table 4. All scenarios yielded similar results to the
- 339 base case, where romosozumab/ denosumab yielded additional LYs without fractures and fewer
- 340 costs relative to teriparatide/ denosumab (i.e., remained the dominant intervention).



### 341 **Table 4 Scenario analysis results**



342 ICER, incremental cost-effectiveness ratio; LY, life year without fractures.

#### 343 **Discussion**

344 This economic evaluation assessed the lifetime cost-effectiveness of 1 year of romosozumab 345 sequenced to 4 years of denosumab versus teriparatide (2 years) sequenced with denosumab (3 346 years), for the treatment of severe osteoporosis in postmenopausal women in Mexico with a 347 history of osteoporotic fracture and who are at very high risk for future fracture. Our base case 348 and in all scenarios results indicate that romosozumab dominates teriparatide; meaning that it 349 produces a gain in LYs (and QALYs) at a lower cost. This is due to the lower drug acquisition 350 cost of romosozumab and the superior BMD efficacy of romosozumab which, translated to 351 fracture reduction efficacy, produces both a QALY gain and a further cost reduction from 352 avoided fractures. Deterministic and probabilistic sensitivity analyses show that model results are 353 robust to uncertainty in parameters. When comparing romosozumab with teriparatide, 354 romosozumab remains cost effective at a threshold of \$600,000 per LY without fractures across 355 all deterministic sensitivity analyses, with probabilistic sensitivity analysis showing a 100% 356 probability that romosozumab is cost effective across all assessed thresholds.

357 The inclusion of romosozumab within the Mexican public health institutions could contribute to 358 reduce the clinical and economic burden associated with osteoporotic fractures. Moreover, by 359 presenting a simple administration scheme with two injections once a month, in comparison with 360 daily injections of teriparatide, romosozumab facilitates adherence to treatment for osteoporosis, 361 and confers more comfort to the patient.

362 Our cost-effectiveness analysis model is equivalent of the one that was submitted to the 363 Canadian Agency for Drugs and Technologies in Health (CADTH) (55), and the General Health 364 Council (Consejo de Salubridad General [CSG]) for reimbursement purposes. Although the cost 365 effectiveness of romosozumab has already been estimated in different countries, our findings 366 contribute to Mexico's pharmacoeconomic literature of osteoporosis. To our knowledge, there 367 has been only one study found that compared romosozumab with teriparatide (24). However, 368 instead of being sequenced with denosumab, Hagino et al study used alendronate agent as the 369 subsequent treatment (24). This specific study was conducted in Japan, and included women 370 with severe postmenopausal osteoporosis that was treated with bisphosphonates as candidates. 371 Hagino et al study found that romosozumab/ alendronate produced greater health benefits at a 372 lower economic cost than teriparatide/ alendronate, which is consistent with our findings.

#### 373 *Limitations and future work*

374 As with all analyses based on economic models, this evaluation has several limitations. The most 375 important one is that this model uses a surrogate outcome – BMD – to estimate relative fracture 376 incidence for romosozumab versus teriparatide, rather than directly observed fracture outcomes. 377 However, as has been demonstrated by the FNIH meta-regression, treatment-induced changes in 378 BMD are a strong predictor of fracture outcomes. Moreover, this method is preferable to

379 estimating relative fracture outcomes via indirect methods which, as previously discussed, would 380 necessitate synthesis of heterogeneous trials, resulting in a high degree of uncertainty.

381 A further limitation is that direct BMD efficacy data for romosozumab versus teriparatide are 382 only available for up to 12 months in the STRUCTURE and romosozumab phase II trials. This is 383 pertinent because romosozumab and teriparatide are provided for different durations (maximum 384 of 1 year and 2 years, respectively) prior to sequencing to denosumab, meaning there is 385 uncertainty in relative efficacy over time. Trial-based evidence also shows that teriparatide 386 continues to produce an improvement in total hip BMD after 12 months of treatment (57). 387 However, even under the conservative assumption that both regimens are equally efficacious 388 after 12 months, romosozumab/ denosumab produces equivalent health outcomes at a lower cost 389 than teriparatide/ denosumab.

390 The hierarchical nature of the model structure is also a limitation. Because patients cannot 391 experience less severe fractures once they have had a more severe fracture, the model most likely 392 underestimates the number of fractures in the population over their lifetime. Additionally, there 393 is uncertainty in the duration of treatment "offset time" (the duration of fracture reduction benefit 394 after treatment discontinuation). While the duration of the offset time was based on clinical 395 evidence (43), it is not possible to precisely quantify the duration of the offset time. This 396 assumption was tested through scenario analyses.

397 Another important limitation is that international data was used where appropriate local data 398 were not available. These included HRQoL, the baseline age of the population, and RRs used to 399 adjust general population fracture rates for fracture history and BMD. Mexican HTA guideline 400 specifies to perform cost-effectiveness analysis as opposed to cost-utility analysis given the lack

401 of HRQoL studies done in the Mexican population. Nevertheless, when using LYs instead of 402 QALYs, romosozumab was still a dominant option.

403 Despite the limitations, this analysis provides clear evidence of the value-for-money of 404 romosozumab sequenced to denosumab versus teriparatide/ denosumab, with results that are 405 robust to alternative deterministic and scenario analyses. These results would not have been 406 possible without the approach of converting BMD efficacy to RRs of fracture, considering the 407 inherent uncertainty associated with indirect comparisons of fracture outcomes. Results of this 408 evaluation are specific to the Mexican healthcare system perspective. However, it is reasonable 409 to expect romosozumab to be cost effective in any setting where the cost per course of 410 romosozumab/ denosumab is lower than that of teriparatide/ denosumab, since the BMD 411 advantage of romosozumab over teriparatide guarantees a QALY gain and lower total cost. More 412 research is needed to facilitate future cost-effectiveness analyses of bone-forming agents 413 sequenced antiresorptives. Lastly, further research on the effectiveness of treatment in other 414 populations (i.e., male osteoporosis, patients with secondary forms of osteoporosis) could inform 415 the potential to extrapolate the results of this analysis.

## 416 **Conclusion**

417 This is the first economic model that evaluates the cost effectiveness of romosozumab/ 418 denosumab as treatment for patients with postmenopausal osteoporosis from a Mexican 419 perspective. The results from this cost-effectiveness analysis indicates that the strategy of using 420 romosozumab for 1 year sequenced to 4 years of denosumab produces a greater number of 421 QALYs (and LYs), reduce the number of fractures and lower the total cost when compared to 2 422 years of teriparatide, sequenced to 3 years of denosumab. According to probabilistic,

- 423 deterministic, and scenario analysis, there is enough evidence to claim that romosozumab/
- 424 alendronate is likely to be the most cost-effective option at any decision-maker threshold. Due to
- 425 this result, romosozumab should be considered as a reimbursable medication from Mexico's
- 426 public drug plan. This will aid in treating women with post-menopausal osteoporosis who has a
- 427 history and is also at high risk for osteoporotic fractures.

#### 428 **Transparency**

# 429 *Author Contributions*

- 430 TAM, EY and JPDM contributed to the design and implementation of the research, to the
- 431 analysis of the results and to the writing of the manuscript; ES and LMC to the writing of the
- 432 manuscript.

## 433 *Declaration of financial/other relationships*

- 434 TAM, LG, EY and LMC are employed by Amgen. JPDM has served as a consultant for Amgen
- 435 and has received research grants from them.

#### 436 *Funding*

437 This work was financed by Amgen, Mexico City, Mexico.

#### 438 *Availability of data and materials*

- 439 The datasets generated during and/or analysed during the current study are available from the
- 440 corresponding author on reasonable request.

# 441 **References**

- 442 1. Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid 443 Biochem Mol Biol. 2014;142:155–70.
- 444 2. Becker DJ, Kilgore ML, Morrisey MA. The societal burden of osteoporosis. Curr Rheumatol 445 Rep. 2010;12:186–91.
- 446 3. Carlos F, Clark P, Galindo-Suárez RM, Chico-Barba LG. Health care costs of osteopenia, 447 osteoporosis, and fragility fractures in Mexico. Arch Osteoporos. 2013;8:1–9.
- 448 4. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J
- 449 Med. 1997;103(2, Supplement 1):S12–9.
- 450 5. Morin S, Lix L, Azimaee M, Metge C, Caetano P, Leslie W. Mortality rates after incident 451 non-traumatic fractures in older men and women. Osteoporos Int. 2011;22:2439–48.
- 452 6. Brown JP, Adachi JD, Schemitsch E, Tarride JE, Brown V, Bell A, et al. Mortality in older
- 453 adults following a fragility fracture: real-world retrospective matched-cohort study in
- 454 Ontario. BMC Musculoskelet Disord. 2021;22:1–11.
- 455 7. Svedbom A, Hernlund E, Ivergård M, Compston J, Cooper C, Stenmark J, et al.
- 456 Osteoporosis in the European Union: a compendium of country-specific reports. Arch
- 457 Osteoporos. 2013;8:1–218.
- 458 8. van Geel TA, van Helden S, Geusens PP, Winkens B, Dinant GJ. Clinical subsequent 459 fractures cluster in time after first fractures. Ann Rheum Dis. 2009;68(1):99–102.



- 461 al. Imminent fracture risk assessments in the UK FLS setting: implications and challenges.
- 462 Vol. 14, Archives of osteoporosis. Springer; 2019. p. 1–5.
- 463 10. Balasubramanian A, Zhang J, Chen L, Wenkert D, Daigle S, Grauer A, et al. Risk of
- 464 subsequent fracture after prior fracture among older women. Osteoporos Int. 2019;30:79–92.
- 465 11. Adachi JD, Brown JP, Schemitsch E, Tarride JE, Brown V, Bell AD, et al. Fragility fracture
- 466 identifies patients at imminent risk for subsequent fracture: real-world retrospective database
- 467 study in Ontario, Canada. BMC Musculoskelet Disord. 2021;22(1):1–10.
- 468 12. Organization WH, others. Assessment of fracture risk and its application to screening for
- 469 postmenopausal osteoporosis: report of a WHO study group [meeting held in Rome from 22
- 470 to 25 June 1992]. World Health Organization; 1994.
- 471 13. Clark P, Rivera FC, Sánchez LM, Gutiérrez CFM, Neri JLV, Vázquez SMC, et al. Severe
- 472 osteoporosis: Principles for pharmacological therapy in Mexico. Reumatol Clínica Engl Ed. 473 2021;17(2):97–105.
- 474 14. CSG. Guía para la conducción de estudios de evaluación económica para la actualización del
- 475 Compendio Nacional de Insumos para la Salud [Internet]. 2023. Available from:
- 476 http://www.csg.gob.mx/descargas/pdf/priorizacion/cuadro-
- 477 basico/guias/conduccion\_estudios/GCEEE\_Enero\_2023.pdf
- 478 15. Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, et al. Parathyroid
- 479 hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and
- 480 suggested guidelines for its use. Endocr Rev. 2005;26(5):688–703.



- 482 Evidencias y Recomendaciones: Guía de Práctica Clínica [Internet]. Available from:
- 483 http://www.cenetec-difusion.com/CMGPC/GPC-IMSS-673-18/ER.pdf
- 484 17. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al.
- 485 Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J
- 486 Med. 2017;377(15):1417–27.
- 487 18. Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al.
- 488 Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med.
- 489 2016;375(16):1532–43.
- 490 19. Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, et al.
- 491 Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal
- 492 women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised,
- 493 open-label, phase 3 trial. The Lancet. 2017;390(10102):1585–94.
- 494 20. Jönsson B, Ström O, Eisman JA, Papaioannou A, Siris E, Tosteson A, et al. Cost-
- 495 effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos 496 Int. 2011;22:967–82.
- 497 21. Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D. Cost effectiveness of 498 denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US. Appl 499 Health Econ Health Policy. 2013;11:485–97.
- 500 22. Moriwaki K, Mouri M, Hagino H. Cost-effectiveness analysis of once-yearly injection of 501 zoledronic acid for the treatment of osteoporosis in Japan. Osteoporos Int. 2017;28:1939–50.

- 502 23. Goeree R, Burke N, Jobin M, Brown JP, Lawrence D, Stollenwerk B, et al. Cost-
- 503 effectiveness of romosozumab for the treatment of postmenopausal women at very high risk
- 504 of fracture in Canada. Arch Osteoporos. 2022;17(1):71.
- 505 24. Hagino H, Tanaka K, Silverman S, McClung M, Gandra S, Charokopou M, et al. Cost
- 506 effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in
- 507 Japan. Osteoporos Int. 2021;32:2011–21.
- 508 25. Söreskog E, Lindberg I, Kanis J, Åkesson K, Willems D, Lorentzon M, et al. Cost-
- 509 effectiveness of romosozumab for the treatment of postmenopausal women with severe
- 510 osteoporosis at high risk of fracture in Sweden. Osteoporos Int. 2021;32:585–94.
- 511 26. SEGOB. EDICIÓN 2021 del Libro de Medicamentos del Compendio Nacional de Insumos
- 512 para la Salud. [Internet]. 2021. Available from:
- 513 https://dof.gob.mx/nota\_detalle.php?codigo=5616775&fecha=26/04/2021#gsc.tab=0
- 514 27. Black DM, Arden NK, Palermo L, Pearson J, Cummings SR, Group S of OFR. Prevalent
- 515 vertebral deformities predict hip fractures and new vertebral deformities but not wrist
- 516 fractures. J Bone Miner Res. 1999;14(5):821–8.
- 517 28. Qaseem A, Forciea MA, McLean RM, Denberg TD, Physicians\* CGC of the AC of.
- 518 Treatment of low bone density or osteoporosis to prevent fractures in men and women: a
- 519 clinical practice guideline update from the American College of Physicians. Ann Intern Med. 520 2017;166(11):818–39.
- 521 29. Jönsson B, Christiansen C, Johnell O, Hedbrandt J. Cost-effectiveness of fracture prevention 522 in established osteoporosis. Osteoporos Int. 1995;5:136–42.





- 544 Followed by One Year of Denosumab Compared With Two Years of Denosumab: BMD and
- 545 Fracture Results From the FRAME and FRAME Extension Studies. In: Oral presentation
- 546 (#1055) at 2022 ASBMR annual meetings. Austin, TX;
- 547 38. Ayers C, Kansagara D, Lazur B, Fu R, Kwon A, Harrod C. Effectiveness and safety of
- 548 treatments to prevent fractures in people with low bone mass or primary osteoporosis: a
- 549 living systematic review and network meta-analysis for the American College of Physicians.
- 550 Ann Intern Med. 2023;176(2):182–95.
- 551 39. Bouxsein ML, Eastell R, Lui LY, Wu LA, de Papp AE, Grauer A, et al. Change in bone 552 density and reduction in fracture risk: a meta-regression of published trials. J Bone Miner 553 Res. 2019;34(4):632–42.
- 554 40. McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, et al. 555 Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 556 2014;370(5):412–20.
- 557 41. Pavone V, Testa G, Giardina SM, Vescio A, Restivo DA, Sessa G. Pharmacological therapy 558 of osteoporosis: a systematic current review of literature. Front Pharmacol. 2017;8:803.
- 559 42. Ideguchi H, Ohno S, Hattori H, Ishigatsubo Y. Persistence with bisphosphonate therapy 560 including treatment courses with multiple sequential bisphosphonates in the real world.
- 561 Osteoporos Int. 2007;18:1421–7.





595 54. Chien, HC, Arora, T, Oates, M, McDermott, M, Curtis, JR. Drug utilization patterns of

596 anabolic agents - romosozumab and parathyroid hormone analogues - among

597 postmenopausal women in the U.S., 2019-2021. In Vancouver, Canada; 2023.

598 55. CADTH. Romosozumab for the treatment of osteoporosis in postmenopausal women with a

599 history of osteoporotic fracture and who are at very high risk for future fracture. [Internet].

600 2022. Available from: https://www.cadth.ca/romosozumab

601 56. Vestergaard Kvist A, Faruque J, Vallejo-Yagüe E, Weiler S, Winter EM, Burden AM.

602 Cardiovascular safety profile of romosozumab: a pharmacovigilance analysis of the US Food

- 603 and Drug Administration Adverse Event Reporting System (FAERS). J Clin Med.
- 604 2021;10(8):1660.
- 605 57. Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie SAM, Zhu Y, Foley K, et al. Two years of
- 606 Denosumab and teriparatide administration in postmenopausal women with osteoporosis
- 607 (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab.
- 608 2014;99(5):1694–700.







Low parameter value High parameter value Incremental net monetary benefit



Dead